In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
Health on MSN5h
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss DrugsIn response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback